EU nod for Bimzelx for moderate to severe plaque psoriasis
The approval is supported by three pivotal Phase III trials
Read Moreby Lucy Parsons | Aug 24, 2021 | News | 0
The approval is supported by three pivotal Phase III trials
Read Moreby Lucy Parsons | Aug 9, 2021 | News | 0
High levels of skin clearance achieved for moderate to severe plaque psoriasis patients
Read Moreby Lucy Parsons | Jun 2, 2021 | News | 0
IL-17A inhibitor has been cleared in the US to treat plaque psoriasis in certain patients aged six years and older
Read Moreby Lucy Parsons | Feb 23, 2021 | News | 0
Company has submitted a supplemental new drug application for mild-to-moderate plaque psoriasis
Read Moreby Lucy Parsons | Feb 5, 2021 | News | 0
Phase III BE VIVID and BE READY studies both met their co-primary endpoints
Read Moreby Selina McKee | Jul 31, 2020 | News | 0
The new approval cover paediatric patients with plaque psoriasis
Read Moreby Anna Smith | Jun 26, 2019 | News | 0
The drug successfully modulates gene expression, leading to substantial improvement of inflammation.
Read Moreby Anna Smith | Apr 18, 2019 | News | 0
For adults who have failed to respond to, or are unsuitable for, other systemic therapies.
Read Moreby Anna Smith | Mar 5, 2019 | News | 0
Sun Pharma’s Ilumya has proven to be efficient for up to three years of ongoing treatment.
Read Moreby Anna Smith | Feb 28, 2019 | News | 0
Janssen has announced FDA approval of its novel drug Tremfya for adults with moderate-to-severe plaque psoriasis.
Read Moreby Selina McKee | Aug 16, 2018 | News | 0
Bausch Health group Ortho Dermatologics has resubmitted an application to market its plaque psoriasis lotion Duobrii in the US
Read Moreby Selina McKee | May 11, 2018 | News | 0
Janssen’s Tremfya has been recommended by NICE as a cost-effective treatment for plaque psoriasis.
Read More





PharmaTimes Media Ltd.
44 Maiden Lane
Covent Garden
London
WC2E 7LN
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
